Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06753916 · ClinicalTrials.gov registry record · Phase 2
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
A Phase 2 study of Corneal Transplant Failure, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 12
- Study locations
NCT06753916: Recruiting Phase 2 study of Corneal Transplant Failure, sponsored by Massachusetts Eye and Ear Infirmary.
NCT06753916 is a Phase 2 study of Corneal Transplant Failure that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06753916, a Phase 2 study of Corneal Transplant Failure, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 12
- Study locations
Study Summary
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Primary Outcome
The occurrence of adverse events throughout study including: 1. Ocular Safety per the incidences and severity of ocular adverse events during the study based on ophthalmic examination and participants' self-report. 2. Short Term Safety Events (Post Surgery \< 1 Month) * Post-Op Microbial Keratitis * Acute Rejection (Epithelial, Endothelial, Sub epithelial, or Mixed) 3. Long Term Safety Events (Post Surgery \> 1 Month) * Rejection (Epithelial, Endothelial, or Mixed) * Graft Failure
Conditions Studied
Interventions
- PROCEDURE Corneal Donor Tissue with Cross Linking
- PROCEDURE Corneal Donor Tissue without Cross Linking
Study Locations (12)
California
- University of California Irvine - Gavin Herbert Eye Institute - Irvine
- The University of California Los Angeles - Doris Stein Eye Research Center - Los Angeles
- University of California San Francisco - Wayne and Gladys Valley Center for Vision - San Francisco
North Carolina
- Wake Forest Baptist Eye Center - Bermuda Run
- Duke University - Duke Eye Center - Durham
Florida
- University of Miami - Bascom Palmer Eye Institute - Miami
Indiana
- Price Vision Group - Indianapolis
Kansas
- Kansas City Eye Clinic - Overland Park
Maryland
- Mid-Atlantic Cornea Consultant - Towson
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- University of Michigan - Kellogg Eye Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2031-01-01 |
| Phase | Phase 2 |
What NCT06753916 shows while recruiting
NCT06753916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Corneal Transplant Failure appearing as the primary indexed condition, and to 2 interventions - of which Corneal Donor Tissue with Cross Linking is the first listed.
NCT06753916 lists 12 locations in 9 states (California, North Carolina, Florida).
Frequently Asked Questions
What is clinical trial NCT06753916 about?
NCT06753916 is a clinical study titled "ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty". The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
What is the current status of trial NCT06753916?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-04-01. Estimated completion is 2031-01-01.
What conditions does trial NCT06753916 study?
This clinical trial studies the following conditions: Corneal Transplant Failure.
What interventions are being tested in trial NCT06753916?
The interventions under investigation include: Corneal Donor Tissue with Cross Linking (PROCEDURE), Corneal Donor Tissue without Cross Linking (PROCEDURE).
Who is sponsoring clinical trial NCT06753916?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06753916 being conducted?
This trial has 12 study locations across California, Florida, Indiana, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Transplant Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06753916's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI